Login to Your Account


DUBLIN – Zelluna Immunotherapy AS is the latest contender to throw its hat into the immuno-oncology ring, but the Oslo, Norway-based startup can draw on several decades' worth of clinical research in its effort to build a pipeline of cell and biologic therapies based on proprietary T-cell receptors (TCRs) against important tumor antigens.

DUBLIN – The founders of the U.K.-listed gene editing technology firm Horizon Discovery plc, Alberto Bardelli and Chris Torrance, have re-emerged in a new startup that has a therapeutic focus.

Lightning Bolte

Axel Bolte's background in venture financing served him well when it came time to set up shop at Inozyme Pharma Inc. But his deep ties to academia were even more important to the company's formation.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: